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Akkermansia muciniphila is an intestinal bacterium that was isolated a decade ago from a human fecal
sample. Its specialization in mucin degradation makes it a key organism at the mucosal interface be-
tween the lumen and host cells. Although it was isolated quite recently, it has rapidly raised signiﬁcant
interest as A. muciniphila is the only cultivated intestinal representative of the Verrucomicrobia, one of
the few phyla in the human gut that can be easily detected in phylogenetic and metagenome analyses.
There has also been a growing interest in A. muciniphila, due to its association with health in animals and
humans. Notably, reduced levels of A. muciniphila have been observed in patients with inﬂammatory
bowel diseases (mainly ulcerative colitis) and metabolic disorders, which suggests it may have potential
anti-inﬂammatory properties. The aims of this review are to summarize the existing data on the in-
testinal distribution of A. muciniphila in health and disease, to provide insight into its ecology and its role
in founding microbial networks at the mucosal interface, as well as to discuss recent research on its role
in regulating host functions that are disturbed in various diseases, with a speciﬁc focus on metabolic
disorders in both animals and humans.
© 2016 Elsevier Ltd. All rights reserved.Contents
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The human intestine is home tomore than a thousandmicrobial
species. A recent review pointed out that over 1000 microorgan-
isms, belonging to Bacteria, Archaea and Eukarya, have been ob-
tained in pure cultures [1]. In 1950, the study of intestinal bacteria
was revolutionized by the development of an array of techniques
for culturing strict anaerobes by Robert Hungate [2]. Prior to this,
mostly only aerobic or facultative anaerobic bacteria could be iso-
lated from intestinal samples. The use of strict anaerobic conditions
according to the Hungate approach enabled the extensive charac-
terization of the major intestinal microbes in the 1970s. Cultivation
of most intestinal bacteria has been carried out using rich media, or
semi-deﬁnedmediawith targeted carbon sources. In the late 1970s,
Carl Woese discovered a third domain of life, Archaea, using a
proposed universal phylogenetic marker, the 16S rRNA gene, that
can be used as a signature of prokaryotic species [3]. This and the
subsequent molecular revolution based on rapid sequencing
methods have drastically changed the perception of microbial
ecology, allowing for a more representative description of various
ecosystems, and circumventing the need to cultivate bacteria in
order to describe the community of a speciﬁc niche [3]. This has
also emphasized that most of the sequences returned from
proﬁling human intestinal microbiota samples are derived from
microbes that have not yet been cultivated. In parallel, although
there has been a decline in new cultivation approaches, there is an
obvious renewal of interest in cultivating gut microbes. Indeed,
obtaining bacteria in pure culture is complementary to molecular
approaches since they provide information (e.g. physiology,Fig. 1. Scanning electronic micrograph of Akkermansia muciniphila ATCC BAA-835 (Bar
represents 1 mm.interaction with host and other bacteria) that molecular ap-
proaches do not. However, the direct use of genome sequencing
from intestinal samples to characterize as yet uncultivated micro-
organisms, can also provide information on their genetic capacity
to use speciﬁc nutrients [4,5]. As a major fraction of the gut mi-
crobial ecosystem has not yet been cultured, it is often regarded as
being refractory to cultivation in the laboratory. Although that is
probably true for some microbes that are either too dependent on
the host or on other bacteria to grow, the use of deﬁned medium
combined with novel isolation strategies (such as culturomics) has
nevertheless, led to the successful isolation of an increasing num-
ber of intestinal bacterial species [6e8]. A recent example of an
organism that was refractory to in vitro isolation is Candidatus
arthromitus (also known as segmented ﬁlamentous bacteria, or SFB)
that is found abundantly in the intestinal tract of mice although not,
or not all, in humans. Using a strategy that combines an SFBehost
cell co-culturing system, SFB was ﬁrst isolated in pure culture in
2015 [9]. Some examples of currently uncultivable bacteria from
human microbiota that are frequently detected in human samples
by sequencing technologies includemembers of the Candidate TM7
phylum and Cyanobacteria [5], as well as some genera of Clos-
tridiales such asOscillospira, neither of which have been obtained in
pure culture, although indications for the sequence of their ge-
nomes have been obtained. A species that was successfully isolated
is Akkermansia muciniphila (Fig. 1). Interestingly it was, and still is,
the ﬁrst intestinal microbial isolate of the phylum Verrucomicrobia.
With its isolation came the awareness that this phylum is repre-
sented in the intestine. It was originally isolated from a fecal sample
from a healthy Caucasian female in a speciﬁc medium that con-
tained puriﬁed mucin as the sole carbon source, using the most
probable number approach [10]. Mucin was chosen as a selective
carbon source since it was hypothesized that microbes capable of
utilizing these host-produced glycans as carbon sources are those
that are located at the interface between the luminal bacteria and
the host, a prediction that materialized with the discovery of
A. muciniphila.2. Ecology of A. muciniphila in the intestine
2.1. Abundance in human samples
Once isolated, it was important to quantify the amount of
A. muciniphila cells within human stool samples in order to eval-
uate whether it is commonly present. It was originally determined
that A. muciniphila accounted for more than 1% of the total
microbiota using ﬂuorescent in situ hybridization (FISH) and
quantitative PCR (qPCR) [11,12]. Notably, at that time, FISH was also
commonly used to quantify major bacterial taxa. Interestingly, it
was observed that Akkermansia spp. could not be targeted by the
classical EUB-338 I universal bacterial probe. Later, the wider
availability of 16S rRNA gene sequencing allowed for the detection
of the genus Akkermansia in a large number of studies. When the
Table 1
Overview of clinical studies (observational or interventional) related to metabolic disorder in which a differential Akkermansia abundance was observed.
Target population Study
(observational or
intervention)
Groups
(number of
individuals)
Microbiota
analysis
approach
Samples analysed
time
Akkermansia population References
Obese women Observational Obese
women
(n ¼ 53)
Whole
shotgun
metagenomic
Stool
One time point
Negatively associatedwithmarkers for insulin resistance
or dyslipidaemia
[96]
Elite athletes Observational Elite athletes
high BMI
(n ¼ 40)
Healthy
males Low
BMI 25
(n ¼ 23)
Healthy
males high
BMI (n ¼ 23)
16S
sequencing
Stool
One time point
Higher proportions in athletes and in low
BMI control group
[122]
Infants of overweight and
normal-weight mothers
Observational Lean
(n ¼ 16)
Overweight
mothers
(n ¼ 26)
Infants (1, 6
months)
qPCR
FISH-FCM
Stool
Infants (1, 6 months)
Decreased prevalence in infants of normal-weight
mothers and of mothers with normal weight gain during
pregnancy
[98]
Lean and overweight
lactating women
Observational Lean women
(n ¼ 34)
Overweight
women
(n ¼ 22)
qPCR Breast milk (after
delivery, 1 and 6
months later)
Trend towards increased prevalence in breast milk (1
month after delivery) from overweight mothers
[37]
Overweight and obese
adults
6-week calorie
restriction (CR) and
6-week follow up
Overweight
(n ¼ 11)
Obese
(n ¼ 38)
qPCR
Metagenomic
Stool
Baseline (T0)
After CR (T ¼ 6
weeks)
After weight
stabilisation (T ¼ 12
weeks)
At baseline, A. muciniphila MGS was inversely related to
fasting glucose, waist-to-hip ratio, and subcutaneous
adipocyte diameter Subjects with higher level of
A. muciniphila at baseline had greater improvement in
insulin sensitivity markers and other clinical parameters
after CR
[15]
Lean, overweight and obese
adults
Observational Lean
(n ¼ 10)
Overweight
(n ¼ 10)
Obese
(n ¼ 10)
16S
sequencing
Stool
One time point
Akkermansia negatively correlated with BMI [95]
Lean, overweight and obese
children(4e5 years)
Observational Lean
(n ¼ 20)
Overweight,
obese
(n ¼ 20)
qPCR, T-RFLP Stool
One time point
Decrease in obese/overweight children [92]
Obese women 8-week of impact
of 4 g of Ephedra
sinica extract/day
Obese
women
(n ¼ 7)
16S
sequencing
Stool
2 samples/subject
(before and after
Ephedra sinica
extract intake)
Positive association of Akkermansia with weight loss [123]
T2D and healthy individuals Observational T2D (n ¼ 71)
Healthy
controls
(n ¼ 74)
Whole
shotgun
metagenomic
Stool
One time point
Increase in T2D [99]
Overweight individuals 1-week fasting
program and 6-
week probiotic
intervention
Overweight
adults
(n ¼ 13)
qPCR Stool
Before fasting (T1)
During fasting (T2)
After 6-week
probiotic
intervention (T3)
Increase between T1 and T3 [124]
Obese individuals 16-week weight
reduction diet
Obese
individuals
(n ¼ 33)
qPCR Stool
Before, during and
after intervention
Increase after weight reduction [94]
Normal weight and
overweight pregnant
women (24 weeks)
Observational Normal
weight
(n ¼ 34)
Overweight
(n ¼ 16)
qPCR Stool
One time point
No difference between normal and overweight Decrease
in excessive weight gain
[97]
Adult women Observational Lean
(n ¼ 17)
Obese
(n ¼ 50)
qPCR Stool
One time point
Trend to increase prevalence in lean individuals [93]
(continued on next page)
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Table 1 (continued )
Target population Study
(observational or
intervention)
Groups
(number of
individuals)
Microbiota
analysis
approach
Samples analysed
time
Akkermansia population References
Lean, morbidly obese post-
gastric-bypass surgery
human subjects
Gastric bypass Normal
weight
(n ¼ 3)
Morbidly
obese(n ¼ 3)
Post-gastric-
bypass
surgery
(n ¼ 3)
16S
sequencing
Stool
One time point
Increase after bariatric surgery
Low in obese
[85]
Normal glucose tolerance
(NGT), Prediabetes (PD)
and newly diagnosed
T2D subjects
Observational NGT (n¼ 44)
Pre-DM
(n ¼ 64)
T2D (n ¼ 13)
16S
sequencing
Stool
One time point
Decrease in Pre-DM and T2D [125]
qPCR: Quantitative PCR, FISH-FCM: Fluorescent in Situ Hybridisation coupled with ﬂow cytometry, FODMAP: Fermentable Oligosaccharides, Disaccharides, Monosaccharides
and Polyols, MGS: Metagenomic Species, T-RFLP: Terminal-Restriction Fragment Length Polymorphism, T2D: Type 2 Diabetes.
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distinct bacterial communities or enterotypes, Akkermansia spp.
were found to occur in the enterotype in which Ruminococcus or
Clostridiales were the main drivers [13]. Using a correlation
network, Akkermansia was found to be positively associated with
Gordonibacter as well as Ruminococcaceae, and negatively associ-
ated with Prevotella [13]. In two independent clinical studies
(Danish and French cohorts), A. muciniphila was present in greater
abundance in subjects with a high metagenome richness [14,15].
Moreover, in the French cohort, correlation networks of meta-
genomic species (MGS) including that of Akkermansia, were
determined. Several MGS positively correlated with Akkermansia,
including Methanobrevibacter smithii, the most abundant and
prevalent methane producer, as well as members of the family
Ruminococcaceae [15]. This could indicate that these bacteria have
similarnutritional requirements or that they engage in cross-
feeding.
In mono-colonised mice, Akkermansia is more prevalent in the
colon than in the ileum [16]. This is supported by studies in con-
ventional mice [17]. In an in vitromodel involving three fermenters
to mimic the human colonic environment, Akkermansia was not
detected in the microbiota of the ascending colon, while it was
detected in the transverse and descending colon compartments,
with highest abundance in the transverse compartment [18,19].
2.2. Ecological advantage of intestinal mucus
Intestinal mucus is composed of an inner layer devoid of bac-
teria and a thicker outer layer with commensal bacteria [20]. Its
major components, mucins, are a source of nutrients for intestinal
bacteria since it is composed of amino acids and oligosaccharides.
Some bacteria possess the enzymatic machinery necessary for the
breakdown of the mucins’ oligosaccharide chains, which in turn,
release fucose, galactose, N-acetylglucosamine, N-acetylgalactos-
amine, sialic acid, sulfate, and also di-sacharides and small oligo-
saccharides that can be further metabolized by the resident
microbiota. Mucin degradation by commensal bacteria has been
reviewed elsewhere [21,22]. Elegant experiments with nano-SIMS
(stable isotope mass spectrometry) in combination with FISH
showed that Akkermansia is among the ﬁrst utilizers of labeled
mucus on the mouse mucosa [23]. Mucin degradation offers an
ecological advantage to bacteria that are dependent on dietary
nutrients. Indeed, in the absence of dietary glycans, host-derived
mucins represent a constant source of nutrients. This advantage
would explain the diverse ecological habitats of Akkermansia spp.
When we screened the databases available for the presence ofAkkermansia species it became apparent that this organism is
commonly found in the intestines all over the animal kingdom [24].
Indeed, A. spp. have been detected in the intestines of various an-
imals including rodents (references Table S1), but also donkeys
[25], rabbits [26], Syrian hamsters [27] pythons [28], horses [29,30],
pigs [31] and rock ptarmigans [32] amongst others. An interesting
ﬁnding has been that its relative abundance increases in humans,
mice, hamsters and snakes under conditions of caloric restriction
(Table 1 and S1). This supports the suggestion of the existence of
mucosal communities driven by A. muciniphila [24]. While these
experiments do not exclude the possibility that there are other
mucus utilizers, it is relevant to note that mucosal analysis showed
A. muciniphila to be abundant in biopsies of healthy subjects but
reduced in those of patients with Inﬂammatory Bowel Disease
(IBD), who in contrast, had increased amounts of Ruminococcus
gnavus [33]. Comparative biochemical analysis of the sialidases of
these bacteria revealedmarked differences consistent with a selﬁsh
phenotype of R. gnavus, while the A. muciniphila lifestyle was
compatible with a phenotype that stimulates tropic chains [34].
3. Development of A. muciniphila during the human life span
The development of the intestinal A. muciniphila community
with age has been investigated in several studies with subjects of
different nationalities. In an early study, its development over a
wide age-range was determined in infants (1, 6 and 12 months of
age), adults (25e35 years of age) and the elderly (80e82 years of
age) in a Finnish population. A. muciniphila was found to colonize
the intestinal tract in early life and to achieve a level close to that
observed in adults within a year [12,35]. A. muciniphila was more
abundant in adults than in Finnish children less than one year old, as
determined by qPCR and FISH. In the same study, the A. muciniphila
levels were found to decline in elderly subjects [12]. In another
study that compared the abundance of selected bacteria in breast-
fed Finnish and German infants at 6 months of age [36], the pres-
ence of bacteria resembling A. muciniphila was also detected at a
very low concentration in breast milk (<3 log number of gene
copies/ml of breastmilk) [37] and in themicrobiota of human breast
tissue [38]. This could be attributed to the presence in breastmilk of
oligosaccharides that resemble mucin in composition and structure
[21]. However, studies have indicated thatA.muciniphila levelswere
higher in formula-fed as compared to breast-fed infants [39,40].
A detailed comparisonwasmade between the fecalmicrobiota of
Italian centenarians (99e104 years), elderly (63e76 years) and
young adults (25e40 years) using qPCR and a phylogenetic array
approach. Notably, there was less A. muciniphila present in young
M. Derrien et al. / Microbial Pathogenesis 106 (2017) 171e181 175adults compared to elderly subjects [41]. However, a slightly lower
abundance of Akkermansia was observed in Chinese centenarians
(100e108 years) compared to Chinese elderly subjects (80e92
years) [42]. These studies suggest that the evolution of Akkermansia
communities with age may differ between populations and this
warrants further investigation. However, care should be taken to
interpret all the results of these different studies and populations as
it has been shown that the levels of Biﬁdobacterium and Bacteroides
spp., and to some extent also A.muciniphila Ievels, correlatewith the
fucosylation status, suggesting that the genotype of the host de-
termines the colonization of mucus [43]. Moreover, the abundance
of A. muciniphila in the human intestine may depend on bodymass,
mucus thickness and the immune status of the host. These factors
are likely to change during a life time and also during or immedi-
ately prior to the onset of disease. Such changes might be expected
to alter the A. muciniphila levels. Some studies in mice reported a
decreased relative abundance of Akkermansia with age. In aging
leptin deﬁcient obese mice (16 versus 8-week oldmice), the level of
Akkermansia decreased as glucose tolerance declined [44]. Inter-
estingly, in immunodeﬁcient Rag1/ mice (lacking mature lym-
phocytes), the abundance of Akkermansia also decreased with age
[45]. However, it should be emphasized that the translation of re-
sults from mouse models is continuously challenged [46] and it is
has now been well established that the human and mouse micro-
biome only share small fraction of common metagenomic infor-
mation [4].
4. Modulation of Akkermansia spp. Following dietary or
pharmaceutical interventions
4.1. Modulation by diet
Various nutritional interventions, mainly in animal models,
have been reported to affect the levels of Akkermansia spp in the
intestine. In some cases, the administration of speciﬁc dietary
components improved host health and also increased the Akker-
mansia population. Such compounds include polyphenols
[19,47,48], fructo-oligosaccharide [49,50], conjugated linoleic acid
[51], oat bran [52], type 2 resistant starch from high-amylose maize
[53], fermentable oligosaccharides, disaccharides, mono-
saccharides and polyols (FODMAP) [54], whole grain barley [55]
and polyamines [56,57], red pitaya [58] Biﬁdobacterium animalis
subsp lactis LMG P-28149 [59], maize-derived non-digestible fer-
uloylated oligo- and polysaccharides [60], amongst others. Inter-
estingly, medicinal herbs (Flos Lonicera and fermented Rhizoma
Atractylodis Macrocephalae) as well as fungi (Ganoderma lucidum)
that are traditionally considered in Asian culture as medicine
[61e63], also increased the proportion of Akkermansia with a
concomitant beneﬁcial effect on host metabolism. Akkermansia spp.
were also reported to be increased upon consumption of pectin or
guar gum only in rats fed a High Fat Diet (HFD) [64] or barley malt
[55], but decreased in HFD supplemented with barley malt [55].
However, a decrease in the level of Akkermansia was observed in
rats fed a HFD enriched in pectin or guar gum [64]. Several studies
have reported a decrease in abundance of Akkermansia following
HFD [65e67]. Recently, a diet enriched in heme (the pigment of red
meat) was shown to increase the abundance of Akkermansia inmice
[17,24]. Various reports describe the impact of pharmaceutical
treatments on the intestinal level of Akkermansia. Metformin is a
common antidiabetic drug and was found to increase the levels of
Akkermansia spp. populations in mice both on a HFD and normal
diet, while the growth of A. muciniphila was stimulated in Brain
Heart Infusion broth supplemented with metformin [67,68].
Another widely used drug, the proton pump inhibitor omeprazole,
was shown to decrease the abundance of Akkermansia spp. in mice[69]. However, this has not been noted in a recent human study
where the effect of proton pump inhibitors had some impact on
bacteria other than Akkermansia [70].
4.2. Modulation by antibiotics
A major known stressor of the intestinal microbiota is the
exposure to antibiotics. Although the impact on the microbiota is
antibiotic-dependent, in both animals and humans, Akkermansia
spp. was found to bloom after exposure to speciﬁc antibiotics.
However, many studies are only based on 16S rRNA sequencing
data and these do not provide a quantitative approach and hence it
is not always clear whether Akkermansia spp. increase in number,
or remain stable while the other members of the gut microbiota are
severely impacted. An example is a recent study reporting that the
use of tylosin boosted the relative abundance of Akkermansia in
young mice [71]. In a more comprehensive study, on the basis of
16S rRNA gene sequencing, an enormously increased level of
Akkermansia spp. (up to 80%) was reported in two subjects treated
with broad-spectrum antibiotic therapy [72]. As the subjects did
not have gastrointestinal disorders, this indicates that these
extreme numbers have no harmful effect on the human host. This
unusual observation led to a further exploration of the absolute
amount of Akkermansia present in the stool of these individuals by
FISH, which conﬁrmed the increase in relative and absolute abun-
dance of Akkermansia in these adults. Although the Akkermansia
strain responsible was not isolated in pure culture, its deduced
genome based on metagenome analysis of an Akkermansia-
enriched stool sample revealed high identity to the cultured strain,
A. muciniphila MucT [73]. The cultivated A. muciniphila strain MucT
culture appeared to be resistant to vancomycin and metronidazole
[72]. Higher abundance of Akkermansia, together with lactic acid
bacteria and other bacteria with unusual cell-envelopes, was also
observed in the microbiota of adult volunteers exposed to thera-
peutic doses of vancomycin [74]. Similarly, an increase of Akker-
mansia was observed in one patient, reaching 6% of total bacteria,
after 6 days of consumption of a b-lactam. However, the level of
Akkermansia declined at the end of the 14- day consumption period
[75,76]. The apparent vancomycin-resistance of A. muciniphila ex-
plains why vancomycin treatment resulted in an enrichment of
Akkermansia in a NOD mouse model for type-1 diabetes [77].
5. Akkermansia in health: the case of metabolic disorder
Several studies reported a reduction in the abundance of
A. muciniphila in various disorders and diseases in humans. The
majority of these include intestinal diseases, such as IBD, as well as
extra-intestinal diseases, such as autism, atopy or obesity and
related diseases. In this section we will focus primarily on Akker-
mansia and metabolic disorder as most studies have addressed
associations with this widely spreading aberration.
“Metabolic disorder” encompasses a variety of clinical manifes-
tations, including central obesity and impaired fasting glucose, and
ultimately increases the risk of developing T2D or cardiovascular
diseases. In experimental models of obesity, increased intestinal
permeability leads tometabolic endotoxemia, a migration of Gram-
negative derived lipopolysaccharide (LPS) from the intestine into
the circulation [78]. A great variety of association studies involving
the intestinal microbiota and metabolic syndrome have been re-
ported, with some contradictory results (for a review see [79]). Few
studies showed an effect of fecal transplantations in germ-free or
conventional animals [80,81]. Moreover, in a pioneering human
fecal microbiota transplantation study, individuals with metabolic
syndrome were infused with microbiota from a lean donor or their
own microbiota. After 6 weeks, an improvement in insulin
M. Derrien et al. / Microbial Pathogenesis 106 (2017) 171e181176sensitivitywas observed only in the lean donor treatment group and
this was associated with the increase of a phylotype related to the
butyrate producer Eubacterium hallii in the small intestinal mucosa
[82]. This study supports the therapeutic potential of manipulating
the gut microbiota for treatment of metabolic syndrome, and more
speciﬁcally, for promoting insulin homeostasis in human.
5.1. Insight from animal studies
Recently, it was established that the intestinal Akkermansia
abundance decreased in various knock-out or diet-induced
mouse models that develop obesity or other signs of metabolic
disorder. No less than 25 studies are reported (Table S1). These
include studies that reported a lower abundance of Akkermansia
in mice that were leptin deﬁcient [49,66] or fed a HFD [66,71,83]
and which were all obese or had T2D-like symptoms. Moreover,
induced weight loss through gastric bypass surgery has been
shown to lead to increased fecal numbers of Alistipes spp., Pro-
teobacteria and Verrucomicrobia in the mouse and this was
associated with immediate amelioration of glucose metabolism
[84]. This is reminiscent of an earlier bypass study in obese
humans where increased levels of Akkermansia among others,
were reported in fecal samples [85]. While these studies are
indicative of an association with Akkermansia, only a limited
number of interventions have been described and provide direct
support for the role of A. muciniphila in preventing metabolic
disorders. In a seminal study, it was found that the daily
administration of live cells of the A. muciniphila type strain
(108 CFU/day) for four weeks could counteract the deleterious
metabolic features of a HFD diet in mice [66]. Remarkably, this
administration of A. muciniphila prevented not only weight gain,
but also restored epithelial integrity (mucus thickness) that was
disturbed by HFD treatment, counteracted metabolic endotox-
emia (serum LPS), and improved the metabolic proﬁle [66]. This
impact was only observed when viable A. muciniphila was
administered, suggesting that metabolically active bacteria were
required. The positive impact of A. muciniphila on metabolic
syndrome features was subsequently reproduced in independent
studies in various parts of the world using different experimental
designs. In a metabolic feeding study, mice were ﬁrst fed with a
HFD for four weeks, followed by daily gavage of A. muciniphila
(4.108 cfu/day) for six weeks, resulting in improved glucose
tolerance and metabolic endotoxemia. However, a daily dose
greater than 4.107 live cells of A. muciniphila is necessary to
improve the impaired glucose tolerance [67]. Of great interest
was the additional observation that this A. muciniphila treatment
also increased the number of T-reg and globlet cells in the gut, in
line with observed immune signaling and increased mucus pro-
duction. In another recent study, a mouse strain prone to obesity
(AxB19) was used to investigate the impact of A. muciniphila
inoculation on metabolic parameters [86]. Male AxB19 mice were
fed with viable or heat killed A. muciniphila for one week fol-
lowed by the high fat and high sucrose diet for 4-weeks, with
concomitant A. muciniphila gavage (109 cfu/day). After ﬁve weeks
of gavage, a signiﬁcant decrease of various metabolic disorder
parameters was observed, including body weight, body fat and
insulin resistance among others [86]. Finally, Chevalier et al.
inoculated live A. muciniphila (2.108 cfu/day) into germ-free mice
conventionalized with microbiota from cold-exposed mice for 21
days. Notably the co-inoculation of A. muciniphila with the cold
microbiota prevented the transferable increase in intestinal
glucose absorption that was observed when the inoculum con-
sisted of the cold-microbiota alone [87].
Overall, these observational and interventional studies sug-
gest a role for A. muciniphila in the improvement of glucose-insulin homeostasis, reduction of fat accumulation and body
weight, ande importantly, this was reproduced by different
laboratories and with different experimental designs. While the
mouse studies are convincing, some recent rat studies reported
conﬂicting data. An increased abundance of Akkermansia was
found in rats on a HFD supplemented with barley compared to
the HFD control, while a low fat diet supplemented with barley
led to a lower abundance of Akkermansia [88]. Similarly, an
increased abundance of Akkermansia was reported in rats on a
HFD [89e91]. The different outcomes are likely the effects of
environmental and genetic factors. Moreover, these animal
model experiments call for human trials with A. muciniphila to
further study causality in a real life situation.
5.2. Insights from clinical studies
In clinical studies (Table 1), the abundance of Akkermansia is
generally decreased in individuals with metabolic impairments,
such as obese children [92] and adults (trend) [93]. Others show
negative correlations between Akkermansia spp. and markers of
metabolic disorder [94,95]. Variability between studies can be
due to several factors including microbiota, host andmucin pro-
duction amongst others. In a recent study, using quantitative
metagenomics, A. muciniphila was found to be negatively asso-
ciated with serum total and LDL cholesterol in obese Danish
women. Moreover, a negative correlation was observed between
dietary fat intake and its fecal abundance [96]. In a large obser-
vational study of a Danish cohort that consisted of obese and lean
individuals, subjects with a high metagenome richness were
found to be healthier than individuals with low metagenome
richness. Furthermore, A. muciniphila was present in greater
abundance in the former group [14]. Recently, these ﬁndings
were reproduced in a French cohort consisting only of obese and
overweight individuals [15]. The relationship between gut
microbiota, metabolic syndrome and diet intake before and after
a 6-week calorie restriction intervention was also investigated
[15]. A. muciniphila MGS negatively correlated with fasting
glucose, waist-to-hip ratio, and subcutaneous adipocyte diam-
eter. Interestingly, individuals who harbored more A. muciniphila
at baseline exhibited a better metabolic proﬁle including
improved insulin sensitivity [15]. In addition, Akkermansia spp.
were less prevalent in women who gained more weight during
pregnancy in a Spanish cohort [97]. Surprisingly, in a Finnish
cohort, infants of overweight mothers harbored Akkermansia
more frequently than infants of normal-weight mothers [98].
While a large study of Chinese subjects found that Akkermansia
was more abundant in T2D patients compared to healthy controls
[99], the antidiabetic drug metformin was recently reported as a
confounding factor [100] and it has been shown that
A. muciniphila can be stimulated by metformin [68]. Therefore,
the high abundance of Akkermansia in these individuals could be
an indirect effect of taking the drug. Support for this explanation
stems from another study with Chinese adults where Akker-
mansia was found to be lower in pre-diabetic and newly diag-
nosed T2D patients [85]. Thus, it is tempting to speculate that
metformin may also have an indirect effect on host metabolism
via A. muciniphila, which could open new avenues to under-
standing the potential beneﬁcial effect of metformin in T2D.
6. Impact of Akkermansia on barrier function, immune
response and gut microbiota: insights from preclinical models
6.1. Barrier integrity
Compromised barrier function is the basis for many diseases
M. Derrien et al. / Microbial Pathogenesis 106 (2017) 171e181 177varying from IBD to metabolic syndrome. One of the mouse models
for IBD that targets intestinal barrier function include mice treated
with dextran sulfate sodium (DSS). In some studies Akkermansia
was found to increase markedly after DSS treatment [101e104],
while in other studies this was not observed [105]. One could
speculate that the thickness of the mucus layer and the observed
low-grade inﬂammation in the DSS mice may negatively inﬂuence
A. muciniphila colonization. Support for the beneﬁcial effect of
Akkermansia on colitis derives from the observation that extracel-
lular vesicles from A. muciniphilawere found to protect against the
DSS-induced phenotype [105]. In most human studies a depletion
of A. muciniphila is observed in IBD mucosa and in fecal samples
from ulcerative colitis patients [33,106]. However, some other
studies do not show this effect, but a technical bias cannot be
excluded as the A. muciniphilamay have a special spatial location in
fecal samples [107].
The intestinal barrier plays a crucial role by spatially pro-
tecting the intestinal cells from the luminal bacteria through the
turnover of mucus (synthesis and shedding), production of
secretory immunoglobulin A (IgA) via immune exclusion, and
secretion of antimicrobial peptides and proteins, mostly in the
ileum, by Paneth cells [108]. Intestinal mucus is composed of an
inner layer devoid of bacteria and a thicker outer layer with
commensal bacteria [20]. Its major components, mucins, are a
source of nutrients for intestinal bacteria since it is composed of
amino acids and oligosaccharides. Some bacteria possess the
enzymatic machinery necessary for the breakdown of the mu-
cins’ oligosaccharide chains, which in turn release fucose,Fig. 2. Schematic representation of the interaction of Akkermansia with the microbiota and
released from mucin degradation. A. muciniphila interacts with its host by strengthening thgalactose, N-acetylglucosamine, N-acetylgalactosamine, sialic
acid, sulfate, and also di-sacharides and small oligosaccharides
that can be further metabolized by the resident microbiota.
Mucin degradation by commensal bacteria has been reviewed
elsewhere [21,22]. As Akkermansia is specialized in mucin
degradation, it is expected that its variation in the intestine
might be associated with the amount of mucin present, although
other bacteria are also involved in mucin degradation [21,22]. In
rodents on a diet with or without prebiotics (arabinoxylans,
inulin), Akkermansia abundance (as measured by FISH) positively
correlated with the level of mucins in the cecum [109]. Earle
et al., using imaging methods, observed a bloom of the Akker-
mansia population in mice following a depletion of microbiota-
accessible carbohydrates, resulting in a thinner mucus layer in
the distal colon [110]. Recently, a study described the enrichment
of Akkermansia in mice on a heme-enriched diet, and its deple-
tion in mice fed with heme and a cocktail of broad-spectrum
antibiotics (ampicillin, neomycin and metronidazole). The
reduction of Akkermansia abundance following antibiotic treat-
ment was accompanied by a reduction in the expression of the
gene Muc2 encoding the major mucin of the colonic mucus in
colonic tissues, as well as reduced mucolysis [111]. Indeed, be-
sides being able to degrade mucins, Akkermansia was also found
to simulate mucin production [67,68]. Hence, Akkermansia has
not only the capacity to degrade mucins, but also to stimulate
mucin synthesis, illustrative of an autocatalytic process.
Regardless of whether its capacity to degrade mucins or stimu-
late their production depends on mucus thickness, the impact ofits host. A. muciniphila may impact the resident microbiota by suppling growth factors
e intestinal barrier, or by modulating mucin turnover and immune responses.
M. Derrien et al. / Microbial Pathogenesis 106 (2017) 171e181178the resident microbiota on mucin turnover in the gut merits
further investigation.
6.2. Immune response
The ﬁrst inoculation study with A. muciniphila involved a 7-day
follow-up after a single inoculation of germ-free (GF) mice [16].
Subsequently, the host's transcriptional responses were deter-
mined in the small and large intestine. Although the normal
behavior of a bacterium cannot be accurately mimicked in GF
models, in which competition for niche and substrates is lacking,
the study nevertheless highlighted the preferential niche of
A. muciniphila in the colon, and the potential communication with
host, with emphasis on immune signaling. Recently, the impact of
A. muciniphila metabolites on the transcriptome of mouse ileal
organoids was determined, with SCFA, notably propionate, as
controls [112]. Both propionate alone, and metabolites produced
from the grown culture, could induce pathways involved in lipid
metabolism, growth, and immune response, conﬁrming the pre-
vious experiment [22]. In addition to themucus layer, antimicrobial
peptides and the immune system are factors that maintain ho-
meostasis. Mice fed a HFD with daily gavage of Akkermansia,
showed enhanced production of the antimicrobial peptide Reg3g in
the colon, and slightly in the ileum [66]. This was not observed in
the group fed with heat-killed Akkermansia. Secretory IgA is
essential to maintain the luminal bacteria under control, and to
keep the homeostasis at mucosal surfaces (see [113e115] for recent
reviews). Recently, the microbiota was studied from discordant
twins for Kwashiorkhor, a form of malnutrition that results from
protein deﬁciency [116]. It was hypothesized that IgA would target
the microbiotas of the undernourished and the healthy twin
differently. To test this hypothesis, viable bacteria were isolated
from a pair of discordant Malawian twins. Interestingly, Akker-
mansia was the major IgA-targeted bacterium in the healthy twin
child, while members of Enterobacteriaceae were the major IgA-
targeted bacteria in the undernourished child. Direct inoculation
of live A. muciniphilawith one other selected bacterium, Clostridium
scindens prevented lethality in mice, and reduced the sloughing of
epithelial cells compared to mice colonized with a consortia of IgA-
targeted bacteria from the undernourished child, and fed with a
diet mimicking the Malawian diet [116]. Interestingly, no increase
of IgA was observed following a 4-week A. muciniphila gavage with
HFD [66]. These results indicate that A. muciniphila is actively
communicating to the host immune system and is in line with
earlier ﬁndings that its administration stimulated the proliferation
of anti-inﬂammatory regulatory T cells in mice [67].
Recently, Reunanen and colleagues examined the effect of live
A. muciniphila on in vitro colonic cell lines (HT-29 and Caco2).
Interestingly, A. muciniphila was able to adhere to the epithelium
and strengthen the intestinal barrier. Notably, it induced a weak
pro-inﬂammatory response (measured by IL-8 release) compared
to a strain of E. coli K12 [117]. The intimate relationship of
A. muciniphila and the host immune system is exempliﬁed in the
recent study from Zhang, where mice mutated in gene Rag1
(Rag1 /), which lack mature lymphocytes, exhibit a notable in-
crease of Akkermansia according to the results of 16S sequencing
[45]. It is also worth mentioning that A. muciniphila has been
associated with increased inﬂammation in a mouse model of a
simpliﬁed microbiota with a Salmonella typhimurium infection
[118]. The unexpected outcome from these experiments may relate
to the use of GF mice that have a strongly compromised mucus
barrier function prior to microbial colonization. Remarkably, it was
found that A. muciniphila did not bind as effectively to mucus as a
very active mucus-binder such as the probiotic Lactobacillus
rhamnosus GG that is decorated with a mucus binding protein[117,119]. Another recent study, however, showedmucus binding of
the type strain of A. muciniphila as well as isolates from healthy and
IBD patients, indicating that experimental conditions may deter-
mine the strength of the binding [120].
6.3. Resident gut microbiota
The potential modulation of the resident gut microbiota
following A. muciniphila intake has also been investigated in three
of the four mouse studies described [66,86,87] in which
A. muciniphila cells were gavaged into mice. While no signiﬁcant
modulation of the gut microbiota was detected after daily gavage of
108 cfu Akkermansia/day for four weeks [66], it was reported in two
studies that some shift occurred between the two major phyla,
Bacteroidetes (increased) and Firmicutes (decreased) following a 5-
week gavage of 109 cfu Akkermansia/day [86], and following inoc-
ulation of live A. muciniphila (2.108 cfu/day) for 21 days in germ-free
mice conventionalized with microbiota from cold-exposed mice
[87]. Notably an increase of Biﬁdobacterium was reported. Apart
from the different doses used in studies, other variations included
the methodology used, the culturing of cells and other factors. As
discussed above, it is likely that administration of Akkermansia
impacts the mucosal microbiota and its networks. In conclusion, all
of these studies highlight that A. muciniphila communicates with
host, exhibits potential anti-inﬂammatory responses, promotes
barrier integrity and potentially modulates resident gut microbiota
(Fig. 2). However, additional work is needed to understand the
association of Akkermansia and inﬂammation in some disturbed
conditions, notably in humans.
7. Perspectives
In summary, overall there are consistent ﬁndings related to
decreased abundance of Akkermansia in metabolic disorder in both
preclinical and clinical studies. The few interventional studies have
reported a beneﬁcial impact on host metabolism, strongly indi-
cating a direct involvement of Akkermansia. However, some
opposing effects have been reported, suggesting that further
research should be carried out to investigate the relationship be-
tween Akkermansia and host metabolism. The presence of
A. muciniphila in the upper intestine could be of importance for
health in later life, because the microbial colonization of the
mucosal layer by A. muciniphila can enable associations with other
beneﬁcial microbes, leading to a stable mucosal colonization
throughout life. Moreover, a host with no or very low levels of
A. muciniphila might therefore have a strong and speciﬁc response
toward A. muciniphila derivatives given that they can be quite
different from other microbial signatures in the gut. Possibly, the
strong effects of A. muciniphila treatment are due to its phyloge-
netic distinctness within the intestinal microbiota. As this
A. muciniphila is the only cultivated representative of a whole
phylum, it hasmany proteins that are typically and solely expressed
by this organism, with no homologues within the microbiome. A
total of eight different species in the genus Akkermansia have been
identiﬁed [121], supporting the unexplored Akkermansia diversity
within the human gut microbiome. To date, only one A. muciniphila
strain, the type strain (MucT), is available in public culture collec-
tions. However, new isolates from humans and other animals are to
be reported and may indicate how this unique mucolytic symbiont
has adapted to its host.
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